DBV TECHNOLOGIES SA-SPON ADR

DBVTNASDAQ

🏆 #2813 by market capUS Equity

$777.49▼ $37.55 (−4.83%)

Simulated price

🔔

Track DBVT

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$636M

Small Cap

📈Revenue Growth (YoY)

+35.8%

High Growth

📊Gross Margin

93.1%

High

💵FCF Margin

—

⚖️P/S Ratio

128.3x

Expensive

Otter Score

Fair

No chart data available for DBVT.

Trading Snapshot

Day Range: $768.33 – $788.46
52-Week Range: $1.68 – $4.50
Volume: $6.10B
Avg Volume: $6.92B
Shares Outstanding: 296.1M
Next Earnings: Oct 25, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 128.3x
EPS (TTM): $-1.07
Dividend Yield: —
Dilution (1yr): −20.3%

Why Investors Own DBVT

✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DBV TECHNOLOGIES SA-SPON ADR

DBVT

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$147M▲ +22.0% YoY

Free Cash Flow

−$121M▲ +13.4% YoY

Shares Outstanding

76.6M▼ −20.3% YoY

Net Cash

$172M▲ +$148M YoY

StockOtter · stockotter.space

About DBV TECHNOLOGIES SA-SPON ADR

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

🦦